Jupiter Neurosciences, Inc.
JUNSHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeJupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, engages in the development of therapeutics for central nervous system disorders and rare diseases in the. With a market capitalization of $4.3M, it sits in micro-cap territory. It operates in two segments, Pharmaceutical Operations and Premium Nutritional Supplements.
Market Cap
$4.3M
Beta
—
P/E (TTM)
—
P/E (Fwd)
54.67
EPS (TTM)
$-18.39
EPS (Fwd)
$0.06
ROE
-1888.7%
ROA
-159.6%
Cash
$1.5M
Total Debt
$1.7M
Free CF
-$3.3M
52W Change
-96.9%
Annual Financials
Cash vs Debt
Where JUNS stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, JUNS finished 174.40% above its 150-day moving average ($1.25) and 185.83% above its 200-day moving average ($1.20). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is JUNS overbought or oversold?
At the September 3, 2026 close, JUNS's RSI(14) was 26.8, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Jupiter Neurosciences, Inc. carries $1.7M in total debt against $1.5M in cash reserves — debt is modestly above the cash position. Managing this leverage effectively will be important for long-term financial stability. The company is burning cash, with free cash flow at -$3.3M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -1888.7% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has pulled back from $233K (2022) to $22K (2025), a 91% decline worth watching.
The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing JUNS.